combination of rucaparib (Rubraca®) andnivolumab as maintenance treatment
rucaparib alone
metastatic/advanced OC (mOC) - maintenance (M)
double blind
24 countries
ARIEL3, 2017 NCT01968213
rucaparib (n=375) vs. Standard of Care (SoC) (n=189)
randomized controlled trial
ovarian cancer (OC)
aged 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved complete or partial response to their last platinum-based regimen, had a cancer antigen 125 concentration of less than the upper limit of normal, had a performance status of 0-1, and had adequate organ function
87 centres across 11 countries
ARIEL4, 2022 NCT02855944
rucaparib (n=-9) vs. Standard of Care (SoC) (n=-9)
randomized controlled trial
oral rucaparib (600 mg twice daily)
chemotherapy (administered per institutional guidelines)